Connaught’s BCG tuberculosis vaccine
Executive Summary
Approval of the bacillus Calmette-Guerin (BCG) immunotherapeutic tuberculosis vaccine for treatment of non-invasive bladder cancer and bladder cancer in situ is reportedly close to approval. The vaccine is used after surgical removal of bladder tumors.